

## [Ifosfamide](#)

Statut de médicament essentiel

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.1. Cytotoxic medicines](#)

Codes ATC: [L01AA06](#)

EMLc

Indication

Rhabdomyosarcoma primary site Code ICD11: [2C25.Z](#)

INN

Ifosfamide

Type de médicament

Chemical agent

Type de liste

Liste complémentaire

Formulations

**Parenteral > General injections > IV:** 500 mg in vial powder for injection ; 1 g in vial powder for injection ; 2 g in vial powder for injection

Historique des statuts LME

Ajouté pour la première fois en 2009 ([TRS 958](#))

Modifié en 2015 ([TRS 994](#))

Sexe

Tous

Âge

Aussi recommandé pour les enfants

Équivalence thérapeutique

La recommandation concerne ce médicament spécifique

Renseignements sur le brevet

Patents have expired in most jurisdictions

Lire la suite [sur les brevets.](#)

Balises

Cancer

Wikipédia

[Ifosfamide](#)

DrugBank

[Ifosfamide](#)

Résumé des preuves et recommandation du comité d'experts



In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for ifosfamide on the complementary list of the EML for use in treatment protocols for rhabdomyosarcoma was specifically endorsed. Additionally, ifosfamide was included on the complementary list of the EMLc for this indication. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for rhabdomyosarcoma is attached.